Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib plus Etoposide for Osimertinib-Resistant EGFR-Mutant NSCLC
NCT06436144Phase 2Not yet recruiting
- Start
- Jun 2024
- Primary completion
- Jun 2029
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of etoposide in non-small cell lung cancer (NSCLC). Primary endpoint: Objective Remission Rate at 1 month. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
etoposide
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06436144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06436144.